诺思格收盘上涨1.27%，滚动市盈率30.08倍，总市值43.09亿元

Company Overview - Norsg has a closing price of 44.62 yuan, with an increase of 1.27%, and a rolling PE ratio of 30.08 times, resulting in a total market value of 4.309 billion yuan [1] - The company specializes in providing integrated drug clinical research and development services for global pharmaceutical companies and research institutions, including clinical trial operation services, site management, data management and statistical analysis, biological sample testing, consulting services, and clinical pharmacology services [1] Financial Performance - In the first quarter of 2025, the company reported revenue of 173 million yuan, a year-on-year decrease of 2.53%, while net profit was 26.0737 million yuan, reflecting a year-on-year increase of 13.12%, with a gross profit margin of 36.53% [1] Industry Comparison - The average PE ratio for the medical services industry is 38.15 times, with a median of 38.48 times, placing Norsg at the 23rd position within the industry [1] - The company’s static PE ratio is 30.73 times, and its price-to-book ratio is 2.31 [2] - The total market value of the medical services industry averages 15.089 billion yuan, with Norsg's market value at 4.309 billion yuan [2] Capital Flow - On May 12, 2023, Norsg experienced a net outflow of 1.4731 million yuan in principal funds, with a total outflow of 23.3755 million yuan over the past five days [1]